NASDAQ New 52-Week Highs And Lows
New Highs 50 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ ACI Worldwide ACIW 36.37 1,173,327 A
Dow JonesApr 30 16:21 ET
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Vertex Pharmaceuticals Inc's (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, potentially extending the lives of some patients by up to 45 years. Despite
BenzingaApr 26 14:34 ET
Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk
1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a res
WSJApr 23 14:54 ET
ProKidney Sinks 15%+, Snapping Five-Session Run-Up That Saw Biotech More Than Double in Less Than a Week
PROK sank more than 15% Thursday as the biotech snapped a five-session winning streak that saw its price rise some 130% in just days.
Jerry KronenbergApr 18 16:56 ET
ProKidney Stock Soars 30%+ Tuesday and Nearly 90% in Less Than a Week
ProKidney rose more than 30% Tuesday as the biotech firm rallied for the fourth straight session – a run-up that's seen the stock rise nearly 90% in less than a week.
Jerry KronenbergApr 16 17:37 ET
Alpine Immune Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 — TD Cowen Downgrades Buy → Hold 04/12/2024 0.9% Leerink Partners $42 → $65 Downgrades Outperf
BenzingaApr 16 06:44 ET
Express News | Alpine Immune Sciences Inc : TD Cowen Cuts to Hold From Buy
Moomoo 24/7Apr 16 01:54 ET
Could This Stock Be the Next Biotech Buyout?
Yahoo FinanceApr 13 05:29 ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alpine Immune Sciences, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - April 12, 2024) - Rigrodsky Law, P.A. is investigating Alpine Immune Sciences, Inc. ("Alpine") (NASDAQ: ALPN) regarding possible breaches of fiduciary duties an
newsfileApr 12 15:22 ET
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Yahoo FinanceApr 12 12:36 ET
Alpine Immune Sciences Price Target Raised to $65.00/Share From $42.00 by Leerink Partners
Alpine Immune Sciences Price Target Raised to $65.00/Share From $42.00 by Leerink Partners
Dow JonesApr 12 10:04 ET
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform From Outperform
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform From Outperform.
MT NewswiresApr 12 07:19 ET
Express News | Alpine Immune Sciences Inc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $65 From $42
Moomoo 24/7Apr 11 23:31 ET
Maintaining Hold Rating Amid Vertex Pharmaceuticals' Acquisition of Alpine Immune Sciences
TipRanksApr 11 19:55 ET
Global Equities Roundup: Market Talk
The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day. 1922 ET [Dow Jones]--The near-term outlooks for net flows at Netwealth look good, but this
WSJApr 11 19:24 ET
Health Care Slips on Risk Bias -- Health Care Roundup
Health-care companies slipped as a bias for high-risk sectors offset a boost from deal activity. Vertex Pharmaceuticals agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering i
Dow JonesApr 11 17:02 ET
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
On Wednesday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) agreed to acquire Alpine Immune Sciences Inc (NASDAQ:ALPN) for $65 per share or approximately $4.9 billion in cash. Evercore notes the d
BenzingaApr 11 14:47 ET
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
Investors can breathe a sigh of relief on Thursday as last month's Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures with
BenzingaApr 11 14:13 ET
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
BenzingaApr 11 13:33 ET
NKTR, VERU and EGIO Among Mid-day Movers
Seeking AlphaApr 11 12:55 ET
No Data
No Data